An official website of the United States government.

This is not the current EPA website. To navigate to the current EPA website, please go to www.epa.gov. This website is historical material reflecting the EPA website as it existed on January 19, 2021. This website is no longer updated and links to external websites and some internal pages may not work. More information »

Enforcement

Bristol-Myers Squibb Clean Air Act Settlement

(New York, N.Y) Bristol-Myers Squibb, an international pharmaceutical manufacturer, has agreed to reduce the output of ozone-depleting refrigerants at multiple industrial facilities around the country at a combined cost of $3.65 million in order to resolve violations of the Clean Air Act, the Justice Department and U.S. Environmental Protection Agency (EPA) announced today.

Overview

Bristol-Myers Squibb is a global biopharmaceutical and related health-care products company. As part of its United States operations, Bristol-Meyers Squibb owns and operates comfort cooling, commercial refrigeration and industrial process refrigeration units containing R-22 refrigerant, a known ozone-depleting substance (ODS). The United States Environmental Protection Agency (EPA) investigated Bristol-Myers Squibb's Evansville, Indiana facility and identified testing and recordkeeping violations pertaining to refrigeration appliances at the facility. Bristol-Myers Squibb then conducted an audit of twenty-five of its other facilities located in Regions 1, 2, 4, and 5. The proposed consent decree resolves Bristol-Myers Squibb's violations of Section 507 of the Clean Air Act (CAA) and regulations promulgated thereunder at 40 C.F.R. Part 82, Subpart F.

Top of Page

Injunctive Relief

Pursuant to the terms of the proposed consent decree, Bristol-Myers Squibb is required to retrofit or retire four appliances by July 1, 2007, which it completed, retrofit or retire seven additional appliances by July 1, 2008, and retrofit or retire six additional appliances by July 1, 2009. Bristol-Meyers Squibb is also required to take steps to assure compliance with the leak repair, testing and record-keeping requirements at all of its facilities.

Top of Page

Supplemental Environmental Project

Pursuant to the terms of the proposed consent decree, Bristol-Myers Squibb is required to replace two additional non-violating comfort cooling refrigeration units at its New Brunswick, New Jersey facility with non-ODS equipment, at a cost of at least $2.25 million.

Top of Page

Emissions Benefits

The retirement or retrofit of ODS-containing comfort cooling, commercial refrigeration and industrial process refrigeration units is estimated to result in a reduction of approximately 4,722 pounds of R-22 chlorofluorocarbons company-wide. The supplemental environmental project at the New Brunswick, New Jersey facility is estimated to result in the reduction of an additional 1,650 pounds of ODS refrigerants.

Top of Page

Environmental Benefits

Ozone-depleting refrigerants destroy stratospheric ozone. The destruction of stratospheric ozone is linked to an increased incidence of skin cancer and cataracts due to excessive ultraviolet (UV) exposure. Excessive UV exposure also poses risks to human immune systems and plant and animal life.

Top of Page

Penalty

Bristol-Myers Squibb will pay a $127,000 penalty.

Top of Page

Contact

For more information, contact:

Tahani Rivers
U.S. Environmental Protection Agency (2242A)
1200 Pennsylvania Ave., N.W.
Washington, DC 20460-0001
(202) 564-6850
rivers.tahani@epa.gov

Top of Page